2026 Q2 Portfolio Activity
In 2026 Q2, SR ONE CAPITAL MANAGEMENT, LP maintained a portfolio of 17 distinct positions. They heavily accumulated shares in Avalyn Pharma, Inc, increasing the position by 37.8%. Conversely, SR ONE CAPITAL MANAGEMENT, LP completely exited their position in Arcellx, Inc..
Position History
hover any row below to update
Loading…
Total Positions
17
Quarter
2026 Q2
Top Holding
N/A (28.4%)
Top 10 Concentration
95.1%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-17 of 17
SR ONE CAPITAL MANAGEMENT, LP Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
N/A
Veradermics, In...
|
|
Unknown | 28.42% | 16.57% |
#1
1
Prev: #2
|
7.0 |
—
|
no change | no change |
P
S
|
2,401,868 | $295,285,652 | — | 13F Filing | 2026-06-30 | 2026-08-12 | ||
|
ZBIO
Zenas BioPharma...
|
Healthcare | 12.31% | 10.76% |
#2
1
Prev: #3
|
6.5 |
—
|
no change | no change |
P
S
|
5,037,854 | $127,860,735 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
CRSP
CRISPR Therapeu...
|
Healthcare | 10.70% | 10.59% |
#3
1
Prev: #4
|
6.0 |
—
|
no change | no change |
P
S
|
2,038,763 | $111,194,134 | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
N/A
Avalyn Pharma, ...
|
|
Unknown | 10.48% | — |
#4
Prev: #—
|
8.0 |
—
|
3,308,649 | — |
NEW
|
3,308,649 | $108,920,725 | — | 13F Filing | 2026-06-30 | 2026-08-12 | ||
|
DSGN
Design Therapeu...
|
Healthcare | 9.09% | 7.59% |
#5
Prev: #5
|
5.1 |
—
|
no change | no change |
P
S
|
6,526,476 | $94,438,108 | 2021 Q4 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
N/A
Odyssey Therape...
|
|
Unknown | 6.83% | — |
#6
Prev: #—
|
6.2 |
—
|
3,794,883 | — |
NEW
|
3,794,883 | $71,002,261 | — | 13F Filing | 2026-06-30 | 2026-08-12 | ||
|
ALMS
Alumis Inc.
|
Healthcare | 5.31% | 4.72% |
#7
Prev: #7
|
3.1 |
—
|
no change | no change |
P
S
|
1,959,896 | $55,151,473 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
ORIC
ORIC Pharmaceut...
|
Healthcare | 4.81% | 6.39% |
#8
2
Prev: #6
|
2.4 |
—
|
100,455 | 2.2% |
P
S
|
4,615,384 | $49,984,609 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
MLYS
Mineralys Thera...
|
Healthcare | 4.06% | 4.63% |
#9
1
Prev: #8
|
2.6 |
—
|
no change | no change |
P
S
|
1,563,966 | $42,195,803 | 2023 Q2 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
SPRY
ARS Pharmaceuti...
|
Healthcare | 3.09% | 3.52% |
#10
1
Prev: #9
|
2.2 |
—
|
no change | no change |
P
S
|
4,012,903 | $32,143,353 | 2022 Q4 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
N/A
Mobia Medical, ...
|
|
Unknown | 2.56% | — |
#11
Prev: #—
|
4.5 |
—
|
1,986,072 | — |
NEW
|
1,986,072 | $26,613,365 | — | 13F Filing | 2026-06-30 | 2026-08-12 | ||
|
NKTX
Nkarta, Inc.
|
Healthcare | 0.91% | 0.77% |
#12
Prev: #12
|
1.4 |
—
|
no change | no change |
P
S
|
3,333,333 | $9,433,332 | 2022 Q2 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
OCS
Oculis Holding ...
|
Healthcare | 0.86% | 1.86% |
#13
2
Prev: #11
|
1.3 |
—
|
no change | no change |
P
S
|
641,022 | $8,890,975 | 2025 Q1 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
RARE
Ultragenyx Phar...
|
Healthcare | 0.44% | 0.32% |
#14
Prev: #14
|
1.2 |
—
|
no change | no change |
P
S
|
137,753 | $4,599,573 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
ENGN
enGene Holdings...
|
Healthcare | 0.12% | 0.56% |
#15
2
Prev: #13
|
1.0 |
—
|
no change | no change |
P
S
|
747,750 | $1,293,607 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
ORKA
Oruka Therapeut...
|
Healthcare | 0.00% | 2.31% |
Sold All 😨
(Was: #10) |
0.0 |
—
|
-430,330 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
ACLX
Arcellx, Inc.
|
Healthcare | 0.00% | 29.43% |
Sold All 😨
(Was: #1) |
0.0 |
—
|
-2,346,630 | -100.0% |
CLOSED
|
— | $— | 2022 Q1 | 13F Filing | 2026-06-30 | 2026-08-12 |
Showing 1-17 of 17 holdings